➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKesson
Dow
Johnson and Johnson
Boehringer Ingelheim

Last Updated: February 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Alvespimycin

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the drug development status for Alvespimycin?

Alvespimycin is an investigational drug.

There have been 7 clinical trials for Alvespimycin. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2008.

The most common disease conditions in clinical trials are Breast Neoplasms, Lymphoma, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Bristol-Myers Squibb, and Institute of Cancer Research, United Kingdom.

Recent Clinical Trials for Alvespimycin
TitleSponsorPhase
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic LeukemiaNational Cancer Institute (NCI)Phase 1
Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast CancerBristol-Myers SquibbPhase 2
Clinical Trial of the Combination of Intravenous Alvespimycin (KOS-1022), Trastuzumab With or Without Paclitaxel in Patients With Advanced Solid Tumor Malignancies or Her2 Positive Metastatic Breast Cancer Who Have Previously Failed Trastuzumab TheraBristol-Myers SquibbPhase 1

See all Alvespimycin clinical trials

Clinical Trial Summary for Alvespimycin

Top disease conditions for Alvespimycin
Top clinical trial sponsors for Alvespimycin

See all Alvespimycin clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
McKesson
Dow
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.